T. Rowe Price Associates
INSY

T. Rowe Price Associates’s Insys Therapeutics, Inc. INSY Stock Holding History

T. Rowe Price Associates’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-129,483
Closed -$1.15M – 2645
2017
Q3 		$1.15M Buy
129,483
+850
+0.7% +$8.77K ﹤0.01% 1756
2017
Q2 		$1.63M Buy
128,633
+31,513
+32% +$373K ﹤0.01% 1613
2017
Q1 		$1.02M Buy
97,120
+4,260
+5% +$45.4K ﹤0.01% 1786
2016
Q4 		$854K Sell
92,860
-19,000
-17% -$215K ﹤0.01% 1841
2016
Q3 		$1.32M Sell
111,860
-2,800
-2% -$42.6K ﹤0.01% 1648
2016
Q2 		$1.48M Sell
114,660
-25,000
-18% -$364K ﹤0.01% 1595
2016
Q1 		$2.23M Sell
139,660
-9,400
-6% -$179K ﹤0.01% 1500
2015
Q4 		$4.27M Sell
149,060
-5,340
-3% -$148K ﹤0.01% 1439
2015
Q3 		$4.39M Buy
154,400
+11,200
+8% +$412K ﹤0.01% 1452
2015
Q2 		$5.14M Buy
143,200
+49,000
+52% +$1.53M ﹤0.01% 1476
2015
Q1 		$2.74M Buy
+94,200
New +$2.49M ﹤0.01% 1541

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's INSY Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 129,483 shares — an estimated $1.15M sold.

T. Rowe Price Associates first reported a position in INSY in Q1 2015 and held it in 11 quarters. The position peaked at $5.14M in Q2 2015. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

  • T. Rowe Price Associates reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 129,483 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $1.15M.
  • T. Rowe Price Associates first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 11 quarters.
  • T. Rowe Price Associates's Insys Therapeutics, Inc. position peaked at $5.14M in Q2 2015.
  • 112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.